Lower n-3 long-chain polyunsaturated fatty acid values in patients with phenylketonuria: a systematic review and meta-analysis.

Department of Pediatrics, University of Pécs, Hungary. Electronic address: .
Nutrition research (Impact Factor: 2.59). 07/2013; 33(7):513-20. DOI: 10.1016/j.nutres.2013.05.003
Source: PubMed

ABSTRACT The mainstream of phenylketonuria (PKU) management is lifelong restriction of protein intake; however, this dietary restriction may be accompanied by insufficient dietary intake of long-chain polyunsaturated fatty acids (LCPUFA). The objective of this review was to assess whether significant depletion of LCPUFA can be detected in PKU patients on low-protein diet and whether LCPUFA supplementation is an effective way to increase the availability of LCPUFA in PKU patients. The method included structured search strategy on Ovid MEDLINE, Scopus, LILACS, and the Cochrane Library CENTRAL databases, with formal inclusion/exclusion criteria, data extraction procedure, and meta-analysis. We evaluated 9 case-control studies and 6 randomized controlled trials, dated from the inception of the databases to 2012. The meta-analysis of the case-control studies showed significantly lower values of both eicosapentaenoic acid and docosahexaenoic acid (DHA) in all biomarkers investigated and that of arachidonic acid in total plasma lipids in PKU patients as compared with healthy controls. There were sufficient data to demonstrate that dietary DHA supplementation of patients with PKU significantly increases the contribution of DHA to total plasma lipids. In summary, suboptimal LCPUFA status, especially that of n-3 LCPUFA, can be detected in PKU patients. Supplementing DHA to the diet of PKU patients may improve their LCPUFA status; however, further research is needed to determine the optimal supplementation dosage and to establish beneficial functional outcomes.

Download full-text


Available from: Szimonetta Lohner, Apr 13, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine whether the n-6 and n-3 polyunsaturated fatty acid levels can be affected by the PKU diet, fatty acid composition was studied in PKU subjects and controls together with their lipid intake. The study population consisted of 40 PKU patients treated with a phenylalanine-restricted diet. Controls were 50 children on whom preoperative tests had been carried out for minor surgery. Methyl esters were obtained from plasma and red blood-cells and separated by gas chromatography. PKU patients showed lower docosahexaenoic acid levels (22: 6 n-3) (p < 0.001) and higher n-6 series levels in plasma (18:2 n-6) (p < 0.001) and in red blood-cells (20: 4 n-6) (p < 0.001) than the control population. Since docosahexaenoic and arachidonic acids are fundamental structural components for normal brain development, it seems necessary to consider a dietary adjustment in these patients.
    Journal of Inherited Metabolic Disease 02/1994; 17(6):704-9. DOI:10.1007/BF00712012 · 4.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dietary-treated phenylketonuric patients (PKUs) display low levels of long-chain polyunsaturated fatty acids (PUFA) in plasma lipids. In a 6-month clinical trial we observed a decrease of triglycerides and an increase of n-3 long-chain PUFA in plasma of PKUs supplemented with fish oil, while no major differences in respect to the baseline values were found in a group supplemented with blackcurrant oil. A more complete source of long-chain PUFA of both the n-6 and n-3 series should be investigated for dietary supplementation of PKU patients.
    Prostaglandins Leukotrienes and Essential Fatty Acids 01/1996; 53(6):401-4. DOI:10.1016/0952-3278(95)90103-5 · 1.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The recent literature on polyunsaturated fatty acid metabolism in phenylketonuria (PKU) is critically analyzed. The data suggest that developmental impairment of the accretion of brain arachidonic (20:4n-6) and docosahexaenoic (22:6n-3, DHA) acids is a major etiological factor in the microcephaly and mental retardation of uncontrolled PKU and maternal PKU. These fatty acids appear to be synthesized by the recently elucidated carnitine-dependent, channeled, mitochondrial fatty acid desaturases for which alpha-tocopherolquinone (alpha-TQ) is an essential enzyme cofactor. alpha-TQ can be synthesized either de novo or from alpha-tocopherol. The fetus and newborn would primarily rely on de novo alpha-TQ synthesis for these mitochondrial desaturases because of low maternal transfer of alpha-tocopherol. Homogentisate, a pivotal intermediate in the de novo pathway of alpha-TQ synthesis, is synthesized by 4-hydroxyphenylpyruvate dioxygenase. The major catabolic products of excess phenylalanine, viz. phenylpyruvate and phenyllactate, are proposed to inhibit alpha-TQ synthesis at the level of the dioxygenase reaction by competing with its 4-hydroxyphenylpyruvate substrate, thus leading to a developmental impairment of 20:4n-6 and 22:6n-3 synthesis in uncontrolled PKU and fetuses of PKU mothers. The data suggest that dietary supplementation with carnitine, 20:4n-6, and 22:6n-3 may have therapeutic value for PKU mothers and for PKU patients who have been shown to have a low plasma status of these essential metabolites.
    Molecular Genetics and Metabolism 04/2001; 72(3):185-98. DOI:10.1006/mgme.2001.3148 · 2.83 Impact Factor